Computer-aided approach for the identification of lead molecules as the inhibitors of cholinesterase’s and monoamine oxidases: Novel target for the treatment of Alzheimer’s disease

Molecular docking is a promising and reliable technology for the purpose of discovering lead compounds via virtual screening. In addition to allowing testing large number compounds, it also allows determination how selected inhibit targeted protein/receptor based on scoring function ranking. Because selective cholinesterase monoamine oxidase inhibitors play critical role in treatment Alzheimer's disease, this research focuses elucidating mechanism binding interactions few quinolone derivatives within active sites (acetyl-cholinesterase (AChE) butyrylcholinesterase (BChE) (MAO) (monoamine A &B). As result these discoveries, possible that newly identified will be used as development novel enzyme specific diseases, hence enabling therapeutic approaches